Tomoo Matsutani, M.D., Ph.D.
Affiliations: | Molecular Pathology | Ludwig Institute for Cancer Research, San Diego, CA, United States |
Website:
http://www.ludwigsd.org/labs/molecular_pathology/people/Google:
"Tomoo Matsutani"Cross-listing: Chemistry Tree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hara A, Koyama-Nasu R, Takami M, et al. (2020) CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy. Cancer Immunology, Immunotherapy : Cii |
| Wei W, Shin YS, Xue M, et al. (2016) Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 29: 563-73 |
| Bendell JC, Kelley RK, Shih KC, et al. (2015) A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer |
| Masui K, Tanaka K, Akhavan D, et al. (2013) mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metabolism. 18: 726-39 |
| Gini B, Zanca C, Guo D, et al. (2013) The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32 |
| Iwanami A, Gini B, Zanca C, et al. (2013) PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 4339-44 |
| Thomas HE, Mercer CA, Carnevalli LS, et al. (2012) mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Science Translational Medicine. 4: 139ra84 |
| Vlashi E, Lagadec C, Vergnes L, et al. (2011) Metabolic state of glioma stem cells and nontumorigenic cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 16062-7 |